ArticleHealth policy OPEN2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations.
Article in Health policy OPEN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Direct and indirect costs of idiopathic inflammatory myopathies in adults: A systematic review.PloS one · 2024Pooled it
- Budget Impact Analysis: Digital Workflow Significantly Reduces Costs of Implant Supported Overdentures (IODs).Clinical implant dentistry and related research · 2025Trial
- Trial
- A Cardiovascular Care Pathway Supported by Remote Patient Management in Dutch Primary Care: Cost-Effectiveness, Budget Impact, and Workload Analysis.JMIR mHealth and uHealth · 2026Article
- Economic advantage of outpatient shoulder arthroplasty: a Markov model analysis.Journal of shoulder and elbow arthroplasty · 2026Article
- Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses.Therapeutic innovation & regulatory science · 2026Article
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.PharmacoEconomics · 2026Article
- Cost-effectiveness of the IMPALA monitoring system for hospitalised children in low-resource settings: a pragmatic before-and-after study.BMJ paediatrics open · 2026Article
- The economic burden of neurological disorders in Europe - COIN-Eu: Study design and analytic framework.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Treating Opioid Use Disorder With Methadone in Pharmacies.JAMA network open · 2026Article
- Article
- Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool.PharmacoEconomics · 2025Article
- Expected value of implementation of icosapent ethyl in Sweden.BMC health services research · 2025Article
- Cost-effectiveness analysis of prostate-specific antigen screening in China: a middle-income population-based microsimulation study.The Lancet regional health. Western Pacific · 2025Article
- Universal cervical-length screening to prevent preterm birth in twin pregnancy: cost-utility analysis.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Article
- Article
- Health and Economic Outcomes of Addressing Encampments of Individuals Using Opioids.JAMA network open · 2025Article
- A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Gastro hep advances · 2025Article
- Evaluation of Large Language Model Performance in Assessing Health Economic Study Quality.Journal of health economics and outcomes research · 2025Article
- Cost-effectiveness analysis of eight first-line treatments for metastatic hormone-sensitive prostate cancer in China.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.